Advanced Solid Tumors
Conditions
Keywords
Cancer, Solid Tumors, Carcinoma, PI-3K, PI3 kinase, PI3K
Brief summary
This study is being conducted to determine the safety and maximally tolerated dose of PX-866 when given orally on two different schedules: daily on days 1-5 and 8-12 of a 28 day cycle and daily on days 1-28 of a 28 day cycle.
Detailed description
PX-866 is a targeted inhibitor of PI-3K. This study is being conducted to determine the maximally tolerated dose of PX-866 when given orally on two different schedules: daily on days 1-5 and 8-12 of a 28 day cycle and daily on days 1-28 of a 28 day cycle.
Interventions
DRUGPX-866
Oral solution, dose escalation, once per day on days 1 to 5 and 8 to 12 or days 1-28 of a 28 day cycle, until progression or development of unacceptable toxicity
Sponsors
Cascadian Therapeutics Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically confirmed diagnosis of advanced solid tumor and has failed or is intolerant of standard therapy, or for whom standard therapy does not exist. * 18 years of age or older. * ECOG performance status 0 to 1. * Predicted life expectancy of at least 12 weeks. * Discontinued prior chemotherapy or other investigational agents for at least three weeks prior to receiving the first dose of study drug (six weeks for mitomycin C, nitrosureas,vaccines,or antibody therapy)and recovered from the toxic effects of the prior treatment (recovered to baseline or ≤grade 1 per Common Toxicity Criteria for Adverse Events (CTCAE)). * Discontinued any radiation therapy for at least four weeks and have recovered from all radiation-related toxicities (recovered to baseline or ≤CTCAE grade 1) prior to receiving the first dose of study drug. Palliative radiation of 10 fractions or less is permitted and a four week interval is not necessary (also allowed during therapy). * Adequate hematologic function as defined by the following: WBC count \>3,000 cells/μL; platelets \>100,000/μL; hemoglobin \>9 g/dL (may be transfused to this level); ANC \>1500 cells/μL. * Adequate hepatic function as defined by the following: bilirubin \<1.5 mg/dL; aspartate aminotransaminase (AST/SGOT) & alanine aminotransferase (ALT/SGPT) \<2.5 x ULN or \<5 x ULN if due to metastatic disease. * Adequate renal function as defined by serum creatinine level \<1.5 mg/dL.
Exclusion criteria
* Any active infection at study entry. * Known diabetes or fasting blood glucose\>160 mg/dL. * Known human immunodeficiency virus (HIV). * Any serious concomitant systemic disorders that in the opinion of the investigator would place the patient at excessive or unacceptable risk of toxicity. * Surgery within the four weeks prior to the first dose * Significant central nervous system (CNS) or psychiatric disorder(s) that preclude the ability of the patient to provide informed consent. * Known or suspected brain metastases that have not received adequate therapy or for which the patient requires treatment with steroids or anticonvulsants. In the case of previously treated brain metastases, a minimum four week interval between completion of radiation therapy and registration on study with radiologic evidence of stable or responding brain metastases is required. In the setting of previous CNS metastasectomy, adequate (minimum four week) recovery from surgery and/or radiation therapy should be documented. * Leptomeningeal brain metastases should be excluded regardless of whether the metastases have been treated or not. * History of seizures, non-healing wounds, or arterial thrombosis. * Unstable atrial or ventricular arrhythmias requiring control by medication; any cardiac ischemic event experienced within the preceding six months; prior history of congestive heart failure requiring therapy. * Breastfeeding or pregnant (confirmed by serum β-HCG within 10 days prior to the start of study treatment if applicable). * Total gastrectomy, partial bowel obstruction or any gastrointestinal condition that may interfere with absorption of the study medication. * Any condition that could jeopardize the safety of the patient and compliance with the protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determine the MTD of PX-866 | 28 days |
| Evaluate the safety profile of PX-866 | 28 days |
| Evaluate pharmacodynamic measures of the effects of PX-866 on the phosphatidylinositol-3 kinase (PI-3K) pathway and related tumor markers. | 28 days |
| Determine the PK profile of PX-866. | 28 days |
Secondary
| Measure | Time frame |
|---|---|
| Evaluate the anti-tumor activity of PX-866 in patients with advanced malignancies. | 56 days |
Countries
United States
Outcome results
None listed